Drug intelligence / Profile preview

DEBIO 1143 + carboplatin + paclitaxel

Development stage: Discontinued
Lead developer: Debiopharm International
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

DEBIO 1143 + carboplatin + paclitaxel is a combination therapy investigated for the treatment of locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN). DEBIO 1143 (also called xevinapant) is an orally available small molecule antagonist of inhibitor of apoptosis proteins (IAPs), designed to promote apoptosis (programmed cell death) and enhance antitumor immunity; it acts as a radiosensitizer and may potentiate the effect of chemoradiotherapy. Carboplatin and paclitaxel are standard chemotherapeutic agents commonly used in the treatment of various solid tumors; carboplatin is a platinum coordination complex causing DNA crosslinking and apoptosis, while paclitaxel stabilizes microtubules, inhibiting mitosis[1][5].

Brand names: xevinapant
Other names: DEBIO 1143 + carboplatin + paclitaxel

Targets

XIAP (Baculoviral IAP repeat-containing protein 4)BIRC3 (Baculoviral IAP repeat-containing protein 3)BIRC2 (Cellular inhibitor of apoptosis protein 1)Inhibitor of apoptosis protein–caspase and inhibitor of apoptosis protein–receptor-interacting protein kinase protein–protein interfaces

Beyond the preview

Go deeper on DEBIO 1143 + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DEBIO 1143 + carboplatin + paclitaxel.

Explore the full profile